Toremifene is a medicine used to treat certain types of breast cancer. It works by blocking the effects of estrogen in some parts of the body, like the breast tissue. It's a type of medicine called a selective estrogen receptor modulator (SERM).
Every report comes from a Lived member, sent anonymously.
Have you tried Toremifene for Breast Cancer?
Toremifene, sold as Fareston and as a generic tablet, is a hormone therapy for breast cancer. In the US it has one approved use: treating metastatic breast cancer (cancer that has spread beyond the breast to other parts of the body) in postmenopausal women whose tumors are estrogen-receptor positive or whose receptor status is unknown. Estrogen-receptor positive means the cancer cells carry receptors that let estrogen fuel their growth. It is not approved for early-stage breast cancer or for preventing breast cancer. Toremifene belongs to the same family of medicines as tamoxifen, often called selective estrogen receptor modulators (SERMs). In three randomized trials in postmenopausal women with advanced breast cancer, toremifene worked about as well as tamoxifen in two of them, while the third found that tamoxifen kept the cancer from growing for somewhat longer. Survival was similar across all three.
Many breast cancers grow in response to estrogen. The hormone attaches to estrogen receptors on the cancer cells and signals them to keep dividing. Toremifene attaches to the same receptors and competes with estrogen for them, blocking much of that growth signal inside the tumor. In cancers that depend on estrogen, this can shrink the tumor or slow its growth for a time. Medicines in this family do not act the same way everywhere in the body: they block estrogen in some tissues and partly imitate it in others. That mixed action helps explain why toremifene can cause hot flashes and why the lining of the uterus needs watching during treatment.
Toremifene is a 60 mg tablet taken by mouth once a day, with or without food. Taking it at about the same time each day is a simple way to keep the routine steady. The dose is the same for everyone and is not built up gradually; higher doses were tested in trials and did not work better. Treatment usually continues for as long as the cancer stays under control. If a dose is missed, take it when remembered unless the next dose is nearly due, and do not take two doses together. Before starting, the care team checks blood potassium and magnesium and corrects any low levels, because low levels add to the heart rhythm risk described under warnings. People at higher risk also have an ECG (electrocardiogram, a recording of the heart's electrical activity) before treatment.
Hot flashes and sweating are the most common side effects, followed by nausea and vaginal discharge. In the largest trial, about a third of people had hot flashes. Dizziness and swelling of the hands or feet also occur. These effects usually show up early in treatment, and only about 1 in 100 people in the trials stopped because of side effects. In the trial that included regular eye exams, cataracts and dry eyes were each found in about 1 in 10 people, so new blurred vision, glare or trouble seeing at night is worth mentioning. People whose cancer has spread to the bones can have a tumor flare in the first weeks: bone pain and redness over the tumor increase for a while before the cancer responds. A flare does not mean the treatment is failing. It can come with a high blood calcium level, which causes strong thirst, frequent urination, constipation, nausea, confusion or unusual sleepiness. Report these to the care team right away. Toremifene can affect the lining of the uterus, and thickening, polyps and endometrial cancer (cancer of the uterine lining) have been reported. Vaginal bleeding, a change in vaginal discharge, or pelvic pain or pressure should be reported to the care team. The most serious risk is a dangerous heart rhythm, explained under warnings. For a fast, pounding or irregular heartbeat, stop taking toremifene and call the prescriber right away. Fainting or a seizure needs emergency care.
Toremifene carries a boxed warning, the FDA's most prominent type of warning, about QT prolongation. The QT interval is a measurement on an ECG of how long the heart takes to recharge electrically between beats. Toremifene lengthens it, more so at higher levels in the blood, and a long QT interval can set off torsade de pointes, a fast, chaotic rhythm that can cause fainting, seizures or sudden death. For this reason toremifene is not prescribed to people with long QT syndrome or with low potassium or magnesium that has not been corrected, and it is used with caution in people with heart failure or liver disease. The same risk shapes its interactions. Other medicines that lengthen the QT interval should be avoided. Examples include heart rhythm drugs such as amiodarone and sotalol, some antibiotics such as clarithromycin and levofloxacin, some antidepressants and antipsychotics, and the anti-nausea medicine ondansetron. Medicines that block the liver enzyme that clears toremifene (CYP3A4), such as the antifungals ketoconazole and itraconazole and some HIV medicines, raise its level in the blood, and grapefruit and grapefruit juice can do the same. St. John's wort, rifampin (an antibiotic) and some seizure medicines such as carbamazepine and phenytoin speed its clearance and can make it less effective. Thiazide diuretics (water pills) can add to the risk of high calcium, and people taking the blood thinner warfarin need closer monitoring. Because short courses of antibiotics or anti-nausea medicine can matter, have the pharmacist or oncology team check any new prescription or supplement. People who have had blood clots, such as a clot in a leg vein or the lungs, generally should not take toremifene. It can also harm a developing baby. Although it is approved only after menopause, anyone taking it who could become pregnant should use a non-hormonal birth control method and tell the care team promptly if pregnancy occurs.
Toremifene is taken every day for an open-ended period rather than a fixed course. In the trials, the typical person took it for about five months, with treatment stopping when the cancer began to grow again or side effects outweighed the benefit. Response varies a great deal: across the trials, roughly one in five to one in three people had their tumors shrink by a measurable amount. The aim in metastatic breast cancer is to control the cancer and its symptoms for as long as possible. Monitoring is part of the treatment. Expect regular blood tests for blood counts, calcium and liver function, along with potassium and magnesium checks and ECGs when heart rhythm risk is higher. Liver injury, including hepatitis and jaundice, has been reported with toremifene, which is why liver tests are checked periodically. A gynecological exam is recommended before starting and once a year after that. Scans and symptom reviews show whether the cancer is responding, and if it grows, the oncologist will discuss other treatment options.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Toremifene, what you've noticed, or ask the community a question.